Literature DB >> 12191691

A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide).

G Di Colo1, Y Zambito.   

Abstract

When topical controlled delivery of ophthalmic drugs is realised via erodible inserts, drug bioavailability is maximised, if release is controlled exclusively by insert erosion, since parallel mechanisms which increase the release rate, also increases the dose fraction cleared from the precorneal area by tear fluid draining. The respective contributions of diffusion and erosion to the release mechanism of different drugs, namely, prednisolone (PDS), oxytetracycline hydrochloride (OTH) and gentamicin sulfate (GTS), from erodible ocular inserts based on poly(ethylene oxide) (PEO) of molecular weight 400 or 900kDa was determined by an in vitro technique adequate to predict the release mechanism in vivo. PDS and OTH were released with erosion-controlled kinetics. With therapeutic doses of these drugs in the inserts (0.3mg, 1.5%), the possibility of a purely erosive mechanism was shown to rely upon drug-PEO molecular interactions, which limit drug diffusion in the swollen matrix. This was the case with OTH, for which strong interactions with PEO were measured, whereas some contribution from the parallel diffusive mechanism was evidenced for PDS, which showed weaker interactions with polymer. Such a contribution disappeared when the PDS concentration in the insert was increased to 6%, which suggested that the erosive mechanism is favoured by a drug concentration in the hydrated insert substantially higher than solubility. On the other hand, the release of about 50% GTS dose was controlled by diffusion, due to the high water solubility of this drug, accompanied by weak drug-PEO interactions. In this case the residence time of drug in the precorneal area is expected to be significantly shorter than that of the PEO carrier.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191691     DOI: 10.1016/s0939-6411(02)00086-3

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Akshaya Tatke; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2017-08-01       Impact factor: 3.534

2.  Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note.

Authors:  Shagufta Khan; Asgar Ali; Dilesh Singhavi; Pramod Yeole
Journal:  AAPS PharmSciTech       Date:  2008-01-25       Impact factor: 3.246

3.  Dendrimers for Ocular Drug Delivery.

Authors:  Michael G Lancina; Hu Yang
Journal:  Can J Chem       Date:  2017-05-11       Impact factor: 1.118

4.  Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma.

Authors:  Prakash Bhagav; Vaibhav Trivedi; Darshan Shah; Sajeev Chandran
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

5.  Niosome-encapsulated gentamicin for ophthalmic controlled delivery.

Authors:  Ghada Abdelbary; Nashwa El-Gendy
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

6.  Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery.

Authors:  Michael G Lancina; Sudha Singh; Uday B Kompella; Shahid Husain; Hu Yang
Journal:  ACS Biomater Sci Eng       Date:  2017-06-09

7.  Thermosensitive hydrogel based on chitosan and its derivatives containing medicated nanoparticles for transcorneal administration of 5-fluorouracil.

Authors:  Angela Fabiano; Ranieri Bizzarri; Ylenia Zambito
Journal:  Int J Nanomedicine       Date:  2017-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.